Mark L. Baum
2022
In 2022, Mark L. Baum earned a total compensation of $1.2M as Chief Executive Officer at Imprimis Pharmaceuticals, a 84% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $500,346 |
|---|---|
| Salary | $608,649 |
| Other | $86,146 |
| Total | $1,195,141 |
Baum received $608.6K in salary, accounting for 51% of the total pay in 2022.
Baum also received $500.3K in non-equity incentive plan and $86.1K in other compensation.
Rankings
In 2022, Mark L. Baum's compensation ranked 2,681st out of 5,717 executives tracked by ExecPay. In other words, Baum earned more than 53.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,681 out of 5,717 | 53rd |
Division Manufacturing | 1,489 out of 3,111 | 52nd |
Major group Chemicals And Allied Products | 683 out of 1,410 | 52nd |
Industry group Drugs | 636 out of 1,311 | 52nd |
Industry Pharmaceutical Preparations | 457 out of 957 | 52nd |
Source: SEC filing on April 28, 2023.
Baum's colleagues
We found two more compensation records of executives who worked with Mark L. Baum at Imprimis Pharmaceuticals in 2022.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019